Yeah, Lalezari worked with Cenicriviroc back in 20

Yeah, Lalezari worked with Cenicriviroc back in 2011 before switching to leronlimab. Seems lots of BP connections, but it didn't break 70% at 48 weeks. Everyone was getting Truvada? It is mentioned a few times in passing, but do direct explanation or discussion.

Quote:

---

to receive CVC 100 mg (CVC100), CVC 200 mg (CVC200), or EFV 600 mg (Sustiva; Bristol-Myers Squibb), in a double-blind manner, all given with open-label FTC/TDF (Truvada; Gilead Sciences) .

---

Quote:

---

CVC was formulated as 50 mg tablets and each study participant received a total of six tablets daily , including placebos, on a twice-daily schedule: CVC/placebo with breakfast to enhance CVC absorption, EFV/placebo on an empty stomach at bedtime, and FTC/TDF at either time.

---

https://journals.lww.com/aidsonline/FullText/...ing.6.aspx

Quote:

---

Conflicts of interest

M.T. is affiliated with an institution that received clinical trial funding from Tobira Therapeutics, Inc., BMS, GeoVax Inc., Gilead, GSK, Merck, ViiV, Kowa Research Institute; and is on the Data Safety Monitoring Boards of GSK/ViiV, and Janssen. M.S. is affiliated with an institution that received research grants from Tobira Therapeutics, Inc., Merck, BMS, Gilead, ViiV, and GSK. E.D. has been a consultant for Gilead, Janssen, and Vertex and has been a speaker in conferences supported by Gilead and Janssen. J.G. has been a consultant or speaker in conferences supported by AbbVie, BMS, GSK, ViiV, Janssen, Merck, and Gilead; is affiliated with an institution that received research grants from AbbVie, BMS, GSK, ViiV, Boehringer Ingelheim, Pfizer, Janssen, Merck Frost, Gilead, and Tibotec (Janssen) Therapeutics; has served an investigator for Abbott, Avexa, Boehringer Ingelheim, Gilead, GSK, Merck, Pfizer, Roche Laboratories, Parexel, Hiesped, and Tibotec Therapeutics; and his institution has received honoraria for speaking or chairing engagements from Abbvie, BMS, GSK, Gilead, Merck, Pfizer, and Tibotec Therapeutics. J.L. reported no potential conflicts of interest. A.L.L. is a board member of SAB Merck. J.C. is affiliated with an institution that received a research grant from Tobira Therapeutics, Inc. and consultancy fees from Gilead Pharmaceuticals; he has been a speaker in conferences supported by Gilead, ViiV, Abbvie, Janssen, and Merck. J.E. is a former employee of Tobira Therapeutics, Inc. E.L. is an employee of Tobira Therapeutics, Inc. J.F. has received travel support from Tobira Therapeutics, Inc. and is is affiliated with an institution that received a research grant from Tobira Therapeutics, Inc.; she has been a consultant for Merck, ViiV, Janssen, Gilead, and BMS; has received payments for lectures or speaker bureaus from Merck, Janssen, ViiV, and Gilead; and her institution has received research grants from the CDC, OH, Department of Health, NIH, HRSA, NIAID, Durr Foundation, MAC Foundation, and Internet for Health.

---